Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can Be Prevented With Adjuvant Anti-VEGFR3 Therapy

Title	Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can Be Prevented With Adjuvant Anti-VEGFR3 Therapy
Authors	Alexandra R. Harris, Savieay Esparza, Mohammad S. Azimi, Robert Cornelison, Francesca N. Azar, Danielle C. Llaneza, Maura Belanger, Alexander Mathew, Svyatoslav Tkachenko, Matthew J. Perez, Claire Buchta Rosean, Raegan R. Bostic, R. Chase Cornelison, Kinsley M. Tate, Shayn M. Peirce-Cottler, Cherie Paquette, Anne Mills, Charles N. Landen, Jeff Saucerman, Patrick M. Dillon, Rebecca R. Pompano, Melanie A. Rutkowski, Jennifer M. Munson
Magazine	Frontiers in Oncology
Date	03/17/2022
DOI	10.3389/fonc.2022.801764
Introduction	For decades, chemotherapy has been a key method to inhibit cancer growth, but recent evidence suggests it may unintentionally promote cancer malignancy by affecting the tumour stroma. Chemotherapeutic agents, particularly platinums, have shown a previously unknown effect of inducing systemic lymphangiogenesis and activation. This effect has been observed in both healthy and cancerous tissues in breast cancer mouse models as well as in human ovarian and breast cancer patients. Carboplatin, a platinum drug, when administered to healthy mice before tumour inoculation, increased cancer metastasis. However, these effects could be mitigated by inhibiting VEGFR3. This study highlights the potential implications for cancer patients treated with platinums and suggests that incorporating anti-VEGFR3 therapy could alter these effects.
Quote	Alexandra R. Harris, Savieay Esparza and Mohammad S. Azimi et al. Platinum Chemotherapy Induces Lymphangiogenesis in Cancerous and Healthy Tissues That Can be Prevented With Adjuvant Anti-VEGFR3 Therapy. Front Oncol. 2022. Vol. 12. DOI: 10.3389/fonc.2022.801764
Element	Platinum (Pt)
Industry	Pharmaceutical Industry